BAVARIAN NORDIC A/S-ADR Business Summary

Bavarian Nordic A/S (BVNRY) is a fully integrated biotechnology company that generates revenue through the development, manufacturing, and commercialization of life-saving vaccines, primarily targeting infectious diseases. The company’s business model is structured into two primary segments: Public Preparedness and Travel Health. The Public Preparedness division is anchored by long-term government contracts, notably with the U.S. BARDA, for the supply of JYNNEOS (MVA-BN), the world’s only FDA/EMA-approved non-replicating smallpox and mpox vaccine. The Travel Health segment, which became the company's primary revenue driver in 2026, comprises a diverse portfolio including Rabipur/RabAvert (rabies), Encepur (tick-borne encephalitis), Vaxchora (cholera), and Vivotif (typhoid), alongside the newly launched Chikungunya vaccine. Bavarian Nordic competes against global pharmaceutical leaders such as GSK, Sanofi, and Merck & Co., as well as specialty firms like Emergent BioSolutions. Within this landscape, the company maintains a dominant niche as the preeminent provider of biodefense vaccines while rapidly scaling its commercial travel medicine footprint to achieve a more balanced and predictable revenue stream. The company is led by President and CEO Paul Chaplin, Ph.D., who joined the firm in 1999 and has served as CEO since 2014; Chaplin is currently overseeing a leadership transition through the end of 2026 following his announced intention to step down. The executive management team includes CFO Henrik Juuel, who has been instrumental in managing the company’s aggressive M&A strategy and capital structure. Strategic oversight is provided by the Board of Directors, chaired by Anne Louise Eberhard, who assumed the role in late 2025, and Deputy Chair Heidi Hunter. Founded in 1994 by Peter Wulff, Bavarian Nordic has evolved from a research-centric biotech into a profitable, large-scale manufacturer with a global distribution network. The company’s growth is supported by a strong institutional investor base, including ATP and BlackRock, and its board features industry veterans such as Johan van Hoof and 2026 appointees Charl van Zyl and Hans Martin Smith, reflecting a leadership pedigree deeply rooted in international healthcare and commercial excellence.